ReviewFrontiers in medicine2022
Manipulation of Gut Microbiota as a Key Target for Crohn's Disease.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 42 citations in OpenAlex.
- Microbial predictors of sustained clinical remission following the Crohn's disease exclusion diet in adults and microbiome shifts toward healthy pediatric controls.Crohn's & colitis 360 · 2026Article
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
- Disrupted terminal bilirubin catabolism linksFrontiers in microbiology · 2026Article
- The gut virome and regulatory T cell axis in health and systemic disease.Microbiome research reports · 2026Review
- A Review of Global Patterns in Gut Microbiota Composition, Health and Disease: Locating South Africa in the Conversation.Microorganisms · 2025Review
- Review
- Gut Permeability and Microbiota in Parkinson's Disease: Mechanistic Insights and Experimental Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Methane, Bacteria, Fungi, and Fermentation: Pathophysiology, Diagnosis and Treatment Strategies for Small Intestinal Bacterial Overgrowth, Intestinal Methanogen Overgrowth and Small Intestinal Fungal Overgrowth.Current issues in molecular biology · 2025Review
- Beyond the Plate: Patient Perspectives on Diet and Daily Life with Crohn's Disease-A National Survey.Journal of clinical medicine · 2025Article
- The Herbal PairFood science & nutrition · 2025Article
- Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.International journal of molecular sciences · 2025Review
- Role and mechanism of gut microbiota-host interactions in the pathogenesis of Crohn's disease.International journal of colorectal disease · 2025Review
- Oral Microbiota and Inflammatory Bowel Diseases: Detection of Emerging Fungal Pathogens and Herpesvirus.Biomedicines · 2025Article
- Exploring gut microbiota as a novel therapeutic target in Crohn's disease: Insights and emerging strategies.World journal of gastroenterology · 2025Review
- Research progress on the use of polyphenols in the treatment of Crohn's disease.Frontiers in pharmacology · 2025Review
- Validate the Treatment of Crohn's Disease with Chaihu Guizhi Decoction Through Network Pharmacology, Molecular Dynamics Simulation, and in vivo Experiments.Journal of inflammation research · 2025Article
- Advancements in analytical methods for studying the human gut microbiome.Journal of biological methods · 2025Review
- Efficacy and safety probiotics as adjuvant treatment for Crohn's disease: a meta-analysis of randomized controlled trials.Current research in food science · 2025Article
- Lily polysaccharides alleviate colitis through the microbiota-N8-acetylspermidine-cGAS-STING signaling axis.Frontiers in microbiology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) is an inflammatory bowel disease (IBD) sub-type characterized by transmural chronic inflammation of the gastrointestinal tract. Research indicates a complex CD etiology involving genetic predisposition and immune dysregulation in response to environmental triggers. The chronic mucosal inflammation has been associated with a dysregulated state, or dysbiosis, of the gut microbiome (bacteria), mycobiome (fungi), virome (bacteriophages and viruses), and archeaome (archaea) further affecting the interkingdom syntrophic relationships and host metabolism. Microbiota dysbiosis in CD is largely described by an increase in facultative anaerobic pathobionts at the expense of strict anaerobic Firmicutes, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.